Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 4Unknown 1

Sponsor Class

NETWORK 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Breast 3Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 1Brenner Tumor 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × paclitaxel poliglumex × Gynecologic × Clear all
NCT00045682 2017-07-13

CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
78 enrolled
Gynecologic

Ovarian Neoplasms

NCT00060359 2015-05-08

Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

GOG Foundation

Phase 1 Completed
32 enrolled
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00017017 2013-05-30

CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00069901 2008-09-22

Phase II CT-2103/Carboplatin in Ovarian Cancer

CTI BioPharma

Phase 2 Completed
82 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡